• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Alpha Teknova Inc.

    2/14/22 4:33:17 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TKNO alert in real time by email
    SC 13G 1 d324174dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    ALPHA TEKNOVA, INC.

    (Name of Issuer)

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

    02080L 102

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    13G

     

    CUSIP No. 02080L 102    Page 2 of 8 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Ted Davis

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      3,573,559 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      3,573,559 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,573,559 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      12.8% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    (1)

    Includes: (a) 1,886,419 shares of common stock of the Issuer owned directly by Mr. Davis and (b) 1,687,140 shares of common stock of the Issuer owned directly by Irene Davis, Mr. Davis’ spouse. Mr. Davis and Mrs. Davis are husband and wife and each of them may be deemed to have shared voting power and dispositive power over the shares of common stock of the Issuer held by each other. Mr. and Mrs. Davis are also both directors of the Issuer.

    (2) 

    Percentage based on 28,011,917 shares of the Issuer’s Common Stock outstanding as of November 9, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.


    13G

     

    CUSIP No. 02080L 102    Page 3 of 8 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Irene Davis

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      3,573,559 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      3,573,559 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,573,559 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      12.8% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    (1)

    Includes: (i) 1,687,140 shares of common stock of the Issuer owned directly by Mrs. Davis and (ii) 1,886,419 shares of common stock of the Issuer owned directly by Ted Davis, Mrs. Davis’ spouse. Mr. Davis and Mrs. Davis are husband and wife and each of them may be deemed to have shared voting power and dispositive power over the shares of common stock of the Issuer held by each other. Mr. and Mrs. Davis are also both directors of the Issuer.

    (2)

    Percentage based on 28,011,917 shares of the Issuer’s Common Stock outstanding as of November 9, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.


    13G

     

    CUSIP No. 02080L 102    Page 4 of 8 Pages

     

    Item 1.

     

      (a)

    Name of Issuer

     

          

    Alpha Teknova, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

     

          

        2290 Bert Dr.

          

        Hollister, California 95023

    Item 2.

     

      (a)

    Name of Persons Filing

     

          

    (i) Ted Davis

     

          

    (ii) Irene Davis (together, the “Reporting Persons”)

     

      (b)

    Address of Principal Business office or, if None, Residence

     

          

        2290 Bert Dr.

          

        Hollister, California 95023

     

      (c)

    Citizenship

     

          

    The Reporting Persons are citizens of the United States.

     

      (d)

    Title of Class of Securities

     

          

    Common Stock, $0.00001 par value

     

      (e)

    CUSIP Number

     

          

    02080L 102

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)

    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b)

    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c)

    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d)

    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

      (e)

    ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f)

    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);


    13G

     

    CUSIP No. 02080L 102    Page 5 of 8 Pages

     

      (g)

    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h)

    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i)

    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company

          

           Act of 1940 (15 U.S.C. 80a-3);

     

      (j)

    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

      (k)

    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

          

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:                     .

     

    Item 4.

    Ownership.

     

          

    (i) Ted Davis

     

      (a)

    Amount beneficially owned: 3,573,559

     

      (b)

    Percent of class:

     

          

    12.8%*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

     

          

    0

     

      (ii)

    Shared power to vote or to direct the vote:

     

          

    3,573,559 (1)

     

      (iii)

    Sole power to dispose or to direct the disposition of:

     

          

    0

     

      (iv)

    Shared power to dispose or to direct the disposition of:

     

          

    3,573,559 (1)

     

    (1) 

    Includes: (i) 1,886,419 shares of common stock of the Issuer owned directly by Mr. Davis and (ii) 1,687,140 shares of common stock of the Issuer owned directly by Irene Davis, Mr. Davis’ spouse. Mr. Davis and Mrs. Davis are husband and wife and each of them may be deemed to have shared voting power and dispositive power over the shares of common stock of the Issuer held by each other. Mr. and Mrs. Davis are also both directors of the Issuer.

    *

    Percentage based on 28,011,917 shares of the Issuer’s Common Stock outstanding as of November 9, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

     

          

    (i) Irene Davis

     

      (a)

    Amount beneficially owned: 3,573,559


    13G

     

    CUSIP No. 02080L 102    Page 6 of 8 Pages

     

      (b)

    Percent of class:

     

          

    12.8%*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

     

          

    0

     

      (ii)

    Shared power to vote or to direct the vote:

     

          

    3,573,559 (1)

     

      (iii)

    Sole power to dispose or to direct the disposition of:

     

          

    0

     

      (iv)

    Shared power to dispose or to direct the disposition of:

     

          

    3,573,559 (1)

     

    (1) 

    Includes: (i) 1,687,140 shares of common stock of the Issuer owned directly by Mrs. Davis and (ii) 1,886,419 shares of common stock of the Issuer owned directly by Ted Davis, Mrs. Davis’ spouse. Mr. Davis and Mrs. Davis are husband and wife and each of them may be deemed to have shared voting power and dispositive power over the shares of common stock of the Issuer held by each other. Mr. and Mrs. Davis are also both directors of the Issuer.

    *

    Percentage based on 28,011,917 shares of the Issuer’s Common Stock outstanding as of November 9, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not applicable.


    13G

     

    CUSIP No. 02080L 102    Page 7 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022     By:  

    /s/ Damon Terrill, as attorney-in-fact for Ted Davis

          Name: Ted Davis
    Dated: February 14, 2022     By:  

    /s/ Damon Terrill, as attorney-in-fact for Irene Davis

          Name: Irene Davis

    EXHIBIT INDEX

     

    Exhibit
    Number
       Description
    99.1    Power of Attorney (incorporated by reference to Exhibit 24.1 to the Reporting Persons’ Initial Statement of Beneficial Ownership of Securities on Form 3, filed with the Securities and Exchange Commission on June 24, 2021).
    99.2    Power of Attorney (incorporated by reference to Exhibit 24.2 to the Reporting Persons’ Initial Statement of Beneficial Ownership of Securities on Form 3, filed with the Securities and Exchange Commission on June 24, 2021).
    99.3*    Joint Filing Agreement.

     

    *

    Filed herewith.

    Get the next $TKNO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TKNO

    DatePrice TargetRatingAnalyst
    7/22/2025$8.00Overweight
    Stephens
    2/10/2025$12.00Buy
    Craig Hallum
    3/12/2024Buy → Neutral
    BTIG Research
    7/20/2021Overweight
    Stephens
    7/20/2021$27.00Overweight
    Stephens & Co.
    7/20/2021Outperform
    Cowen & Co.
    7/20/2021$26.00Buy
    BTIG
    More analyst ratings

    $TKNO
    SEC Filings

    View All

    SEC Form 10-Q filed by Alpha Teknova Inc.

    10-Q - Alpha Teknova, Inc. (0001850902) (Filer)

    8/8/25 4:07:19 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alpha Teknova, Inc. (0001850902) (Filer)

    8/7/25 4:07:41 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Alpha Teknova Inc.

    EFFECT - Alpha Teknova, Inc. (0001850902) (Filer)

    7/17/25 12:15:12 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens resumed coverage on Alpha Teknova with a new price target

    Stephens resumed coverage of Alpha Teknova with a rating of Overweight and set a new price target of $8.00

    7/22/25 7:51:11 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Craig Hallum initiated coverage on Alpha Teknova with a new price target

    Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00

    2/10/25 8:24:48 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova downgraded by BTIG Research

    BTIG Research downgraded Alpha Teknova from Buy to Neutral

    3/12/24 7:34:27 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Demski Martha J sold $40,512 worth of shares (8,000 units at $5.06), decreasing direct ownership by 40% to 12,000 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:59:45 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Vos Alexander

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Robertson Brett

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:06 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Telegraph Hill Partners Iv, L.P. bought $14,999,999 worth of shares (12,096,773 units at $1.24) (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 9:13:16 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Lowell Matthew bought $49,999 worth of shares (40,322 units at $1.24), increasing direct ownership by 46% to 128,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:21 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $100,000 worth of shares (80,645 units at $1.24), increasing direct ownership by 50% to 243,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:04 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Financials

    Live finance-specific insights

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alpha Teknova Inc.

    SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)

    7/19/24 4:11:25 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    2/14/24 4:06:12 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    10/6/23 4:10:58 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Leadership Updates

    Live Leadership Updates

    View All

    Teknova Announces New Board Member, Martha J. Demski

    HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef

    8/16/23 8:00:00 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care